Human medicines European public assessment report EPAR Doxolipad doxorubicin Breast NeoplasmsOvarian Neoplasms Date of refusal 08082019 Status Refused

Human medicines European public assessment report (EPAR): Doxolipad, doxorubicin, Breast Neoplasms,Ovarian Neoplasms, Date of refusal: 08/08/2019, Status: Refused

Human medicines European public assessment report (EPAR): Doxolipad, doxorubicin, Breast Neoplasms,Ovarian Neoplasms, Date of refusal: 08/08/2019, Status: Refused

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Doxolipad, doxorubicin, Breast Neoplasms,Ovarian Neoplasms, Date of refusal: 08/08/2019, Status: Refused"